No such message found

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: RBC unregistered to registered account
Reply New Message
Prev Message Back To Forum Threaded View Next Message

"I guess the most simple way I can think of is for ZCC to issue shares of ZEL in proportion to all current ZCC shareholders........"

Exactly what I was thinking.

5 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply